Notably, while this strategy of exploiting MTAP loss for treatment is feasible in principle, as shown by our previous study using preclinical in vivo GBM models [12], a previous clinical trial including several other cancer types suggests that mitigating the toxicity of this strategy, such as by implementing a less intensive treatment regimen, is necessary for its clinical application [15]. Here, MTAP is linked to glioblastoma.